CA3071337A1 - Igg fc variants for veterinary use - Google Patents

Igg fc variants for veterinary use Download PDF

Info

Publication number
CA3071337A1
CA3071337A1 CA3071337A CA3071337A CA3071337A1 CA 3071337 A1 CA3071337 A1 CA 3071337A1 CA 3071337 A CA3071337 A CA 3071337A CA 3071337 A CA3071337 A CA 3071337A CA 3071337 A1 CA3071337 A1 CA 3071337A1
Authority
CA
Canada
Prior art keywords
seq
polypeptide
amino acid
igg
acid substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3071337A
Other languages
English (en)
French (fr)
Inventor
Hangjun Zhan
Lam Nguyen
Yongzhong Li
Fawn Qian
Shyr Jiann Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elanco US Inc
Original Assignee
Kindred Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65361820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3071337(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kindred Biosciences Inc filed Critical Kindred Biosciences Inc
Publication of CA3071337A1 publication Critical patent/CA3071337A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CA3071337A 2017-08-15 2018-08-15 Igg fc variants for veterinary use Pending CA3071337A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762545858P 2017-08-15 2017-08-15
US62/545,858 2017-08-15
PCT/IB2018/056142 WO2019035010A1 (en) 2017-08-15 2018-08-15 IGG VARIANTS FOR VETERINARY USE

Publications (1)

Publication Number Publication Date
CA3071337A1 true CA3071337A1 (en) 2019-02-21

Family

ID=65361820

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3071337A Pending CA3071337A1 (en) 2017-08-15 2018-08-15 Igg fc variants for veterinary use

Country Status (9)

Country Link
US (1) US12297272B2 (enExample)
EP (1) EP3668536A4 (enExample)
JP (2) JP2020531002A (enExample)
CN (2) CN111182915A (enExample)
AU (3) AU2018318440A1 (enExample)
BR (1) BR112020002871A2 (enExample)
CA (1) CA3071337A1 (enExample)
MX (1) MX2020001707A (enExample)
WO (1) WO2019035010A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018107117A1 (en) 2016-12-09 2018-06-14 Akston Biosciences Corporation Insulin-fc fusions and methods of use
US12297272B2 (en) 2017-08-15 2025-05-13 Eianco US inc. IgG Fc variants for veterinary use
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
KR20210029210A (ko) 2018-06-29 2021-03-15 악스톤 바이오사이언시스 코퍼레이션 초장기 작용 인슐린-fc 융합 단백질 및 사용 방법
US20210388053A1 (en) * 2018-10-18 2021-12-16 Kindred Biosciences, Inc. Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use
CN120904316A (zh) * 2018-12-27 2025-11-07 伊兰科美国公司 兽用IgG Fc变体
CN113544153B (zh) 2019-01-03 2024-12-10 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
US20220169740A1 (en) * 2019-03-20 2022-06-02 Kindred Biosciences, Inc. NGF Antagonists for Medical Use
AU2020321376A1 (en) * 2019-07-30 2022-02-03 Elanco Us Inc. Parvovirus antibodies for veterinary use
KR20250142943A (ko) 2019-12-19 2025-09-30 악스톤 바이오사이언시스 코퍼레이션 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
WO2021165417A1 (en) 2020-02-19 2021-08-26 Adivo Gmbh Modified fc regions
MX2022011335A (es) * 2020-03-18 2022-10-07 Kindred Biosciences Inc Anticuerpos del receptor anti-interleucina 4 para uso veterinario.
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
LT3972987T (lt) 2020-04-10 2023-09-25 Akston Biosciences Corporation Antigenui specifinė imunoterapija, skirta sulietiems covid-19 baltymams ir naudojimo būdai
GB202005879D0 (en) * 2020-04-22 2020-06-03 Petmedix Ltd Heterodimeric proteins
KR20230005875A (ko) * 2020-04-22 2023-01-10 킨드레드 바이오사이언시스, 인코포레이티드 수의학 용도를 위한 장시간-작용성 항-il31 항체
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
CN120590527A (zh) 2020-05-11 2025-09-05 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物和使用方法
KR20230038522A (ko) 2020-07-10 2023-03-20 인베티엑스 인코포레이티드 고양이에서 치료제의 반감기를 증가시키기 위한 조성물 및 사용 방법
CA3190396A1 (en) * 2020-08-24 2022-03-03 James M. Wilson Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases in felines
CN112625093B (zh) * 2020-12-29 2022-12-23 清远市图微安创科技开发有限公司 用于预防和/或治疗非酒精性脂肪肝炎的多肽化合物
EP4373861A4 (en) 2021-07-23 2025-08-20 Akston Biosciences Corp INSULIN-FC FUSION PROTEINS AND METHODS OF USE FOR TREATING CANCER
JP2024530036A (ja) * 2021-08-06 2024-08-14 ペットメディックス・リミテッド 抗体Ｆｃバリアント
WO2024145280A2 (en) 2022-12-27 2024-07-04 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
AU2024210302A1 (en) 2023-01-20 2025-09-04 Invetx, Inc. Bispecific binding agents for use in companion animals
GB202311984D0 (en) * 2023-08-04 2023-09-20 Petmedix Ltd Optimised fc molecules
WO2025166165A1 (en) * 2024-02-01 2025-08-07 Zoetis Services, Llc Compositions and methods for modifying antibody effector functions
WO2026039359A1 (en) * 2024-08-12 2026-02-19 Akston Biosciences Corporation Fc fusion protein therapeutics for companion animal obesity and methods of use
WO2026038455A1 (ja) * 2024-08-14 2026-02-19 国立大学法人山口大学 細胞傷害活性及び細胞貪食活性を低減させた抗ネコ抗体

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6207383B1 (en) * 1998-07-27 2001-03-27 University Of Utah Research Foundation Mutations in and genomic structure of HERG—a long QT syndrome gene
US7297482B2 (en) * 1998-10-08 2007-11-20 Rigel Pharmaceuticals, Inc. Structurally biased random peptide libraries based on different scaffolds
JP2003518929A (ja) * 1999-12-23 2003-06-17 ユニヴェルシテ・ドゥ・ジュネーブ 基底側部選別シグナル、およびその阻害物質
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
JP2004321100A (ja) 2003-04-25 2004-11-18 Rikogaku Shinkokai ＩｇＧのＦｃ領域を含むタンパク質の変異体
DK1641823T3 (da) 2003-06-12 2011-12-12 Lilly Co Eli GLP-1-analog fusionsproteiner
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
DK1831252T3 (da) 2004-12-22 2009-10-05 Lilly Co Eli GLP-1 analog fusionsproteinformuleringer
US20110123440A1 (en) * 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
US8658174B2 (en) * 2005-07-27 2014-02-25 Qinghua Wang GLP/1/exendin 4 IgG Fc fusion constructs for treatment of diabetes
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP2158318A2 (en) * 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
ATE499088T1 (de) 2007-07-10 2011-03-15 Lilly Co Eli Glp-1-fc fusionsprotein-formulierung
CA2746330C (en) * 2008-12-23 2017-08-29 Genentech, Inc. Immunoglobulin variants with altered binding to protein a
CA2754408A1 (en) 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
WO2010117448A2 (en) 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
JP2013528357A (ja) 2010-03-29 2013-07-11 ザイムワークス，インコーポレイテッド 強化又は抑制されたエフェクター機能を有する抗体
JP2013537416A (ja) 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
CA2835094C (en) 2011-05-06 2020-12-22 David Gearing Anti-nerve growth factor antibodies and methods of preparing and using the same
ES2704007T3 (es) 2011-05-06 2019-03-13 Nexvet Australia Pty Ltd Anticuerpos anti-factor de crecimiento nervioso y procedimientos de preparación y uso de los mismos
EP2537864B1 (en) 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
BR112014001274A2 (pt) 2011-07-18 2017-04-18 Arts Biologics As composto de hormônio luteinizante, e, composição farmacêutica
AU2012285475B2 (en) 2011-07-19 2017-09-14 The National Institute For Biotechnology In The Negev, Ltd. Novel IL-17R-ECD mutants
AU2012328819B2 (en) 2011-10-26 2017-08-03 Elanco Tiergesundheit Ag Monoclonal antibodies and methods of use
BR112014010580B1 (pt) * 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
KR102041412B1 (ko) * 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
KR20140135766A (ko) * 2012-02-22 2014-11-26 엔브이아이피 피티와이 리미티드 종양괴사인자 수용체 융합 단백질 및 이를 이용하는 방법
US10011660B2 (en) 2012-04-30 2018-07-03 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
CA2875783C (en) 2012-06-06 2018-12-11 Zoetis Llc Caninized anti-ngf antibodies and methods thereof
JP2015524821A (ja) 2012-08-02 2015-08-27 ジェイエヌ バイオサイエンシーズ エルエルシー システイン変異及びμ尾部を介して多量体化した抗体又は融合タンパク質
WO2014093387A1 (en) 2012-12-10 2014-06-19 Kindred Biosciences, Inc. Vegf receptor fusion proteins for veterinary use
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
CA2919076C (en) 2013-07-31 2024-01-30 Amgen Inc. Stabilization of fc-containing polypeptides
US20160185837A1 (en) 2013-08-16 2016-06-30 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
CN106029697B (zh) 2013-12-20 2021-06-04 英特维特国际股份有限公司 具有经修饰的ch2-ch3序列的犬抗体
WO2015120790A1 (en) 2014-02-11 2015-08-20 Beijing Advaccine Biotechnology Co. Ltd Vaccines with interleukin-17 as an adjuvant
EP3194440A1 (en) 2014-09-15 2017-07-26 F. Hoffmann-La Roche AG Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists
CN107074952B (zh) 2014-09-30 2021-04-09 英特维特国际股份有限公司 结合犬pd-l1的pd-l1抗体
CA2960569A1 (en) 2014-11-06 2016-05-12 F. Hoffmann-Laroche Ag Fc-region variants with modified fcrn- and protein a-binding properties
KR101825048B1 (ko) 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
RS60614B1 (sr) 2015-03-23 2020-08-31 Jounce Therapeutics Inc Antitela za icos
CA3002622A1 (en) 2015-10-19 2017-04-27 Novartis Ag Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
CA3005696A1 (en) 2015-12-18 2017-06-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
BR112018015170A2 (pt) 2016-01-26 2018-12-18 Defensin Therapeutics Aps métodos para tratamento de doenças, para promoção de crescimento magro, para tratamento ou normalização de uma microbiota disbiótica no intestino, para aumentar riqueza gênica da microbiota intestinal, para aumentar número de filos da microbiota intestinal, para aumentar produção de ácidos graxos de cadeia curta da microbiota intestinal/metaboloma, para aumentar número de bactérias, para diminuir número de bactérias, defensina a, defensina ss, ou um fragmento bioativo das mesmas, e, defensina a e/ou defensina ss e/ou um glp-1/análogo de glp-1.
KR102131544B1 (ko) 2016-02-18 2020-07-07 엘랑코 유에스 인코포레이티드 키메라 개 항-cd20 항체
MX2018014256A (es) 2016-05-20 2019-08-16 Harvard College Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.
EP3481413A4 (en) 2016-07-08 2020-01-08 Askgene Pharma, Inc. FUSION PROTEIN WITH LEPTIN AND METHOD FOR THE PRODUCTION AND USE THEREOF
US20200181258A1 (en) 2016-10-17 2020-06-11 Vetoquinol Sa Modified antibody constant region
WO2018102668A1 (en) 2016-12-02 2018-06-07 The Texas A&M University System Fusion proteins for selectively depleting antigen-specific antibodies
JP7657548B2 (ja) * 2017-04-21 2025-04-07 エランコ・ユーエス・インコーポレイテッド 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子
US11299540B2 (en) 2017-06-18 2022-04-12 Kindred Biosciences, Inc. IL17A antibodies and antagonists for veterinary use
US12297272B2 (en) 2017-08-15 2025-05-13 Eianco US inc. IgG Fc variants for veterinary use
KR20210029210A (ko) 2018-06-29 2021-03-15 악스톤 바이오사이언시스 코퍼레이션 초장기 작용 인슐린-fc 융합 단백질 및 사용 방법
JP2022500037A (ja) 2018-09-14 2022-01-04 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学的使用のための抗ｉｌ４受容体抗体
US20210388053A1 (en) 2018-10-18 2021-12-16 Kindred Biosciences, Inc. Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use
EP3870601A4 (en) 2018-10-25 2022-07-13 Kindred Biosciences, Inc. IL4/IL13 RECEPTOR MOLECULE FOR USE IN VETERINARY MEDICINE
JP7536294B2 (ja) 2018-12-05 2024-08-20 株式会社バイカ・セラピュティクス 抗体のＦｃ領域改変体
AU2019397516A1 (en) 2018-12-12 2021-06-17 Elanco Us Inc. Erythropoietin analogs for veterinary use
CN120904316A (zh) 2018-12-27 2025-11-07 伊兰科美国公司 兽用IgG Fc变体
CN113544153B (zh) 2019-01-03 2024-12-10 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
US20220169740A1 (en) 2019-03-20 2022-06-02 Kindred Biosciences, Inc. NGF Antagonists for Medical Use
CN114599389A (zh) 2019-08-22 2022-06-07 奇达拉治疗公司 变体fc结构域及其用途
CN114364796B (zh) 2019-09-02 2023-07-11 甘李药业股份有限公司 嵌合蛋白
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
MX2022012793A (es) 2020-04-17 2022-11-07 Zoetis Services Llc Variantes de anticuerpos felinos.
CN115996949A (zh) 2020-04-17 2023-04-21 硕腾服务有限责任公司 犬抗体变异体
EP4139344A4 (en) 2020-04-22 2024-10-16 Elanco US Inc. Il4/il13 receptor molecules for veterinary use
KR20230005875A (ko) 2020-04-22 2023-01-10 킨드레드 바이오사이언시스, 인코포레이티드 수의학 용도를 위한 장시간-작용성 항-il31 항체
CN120590527A (zh) 2020-05-11 2025-09-05 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物和使用方法
JP7796415B2 (ja) 2020-06-10 2026-01-09 株式会社バイカ・セラピュティクス エリスロポエチンポリペプチドを含む融合タンパク質
WO2022005883A1 (en) 2020-06-29 2022-01-06 Zoetis Services Llc Feline antibody variants for improving stability
KR20230038522A (ko) 2020-07-10 2023-03-20 인베티엑스 인코포레이티드 고양이에서 치료제의 반감기를 증가시키기 위한 조성물 및 사용 방법
WO2022046941A1 (en) 2020-08-26 2022-03-03 Angiex, Inc. Antimitotic tetrapeptide-antibody conjugates and methods of using same

Also Published As

Publication number Publication date
US20200362034A1 (en) 2020-11-19
JP2026048634A (ja) 2026-03-17
AU2025220819A1 (en) 2025-09-25
WO2019035010A1 (en) 2019-02-21
BR112020002871A2 (pt) 2020-07-28
RU2020110584A (ru) 2021-09-17
CN111182915A (zh) 2020-05-19
AU2023226676A1 (en) 2023-09-28
EP3668536A1 (en) 2020-06-24
US12297272B2 (en) 2025-05-13
CN119390821A (zh) 2025-02-07
AU2018318440A1 (en) 2020-02-13
JP2020531002A (ja) 2020-11-05
AU2023226676B2 (en) 2025-05-22
MX2020001707A (es) 2020-03-20
EP3668536A4 (en) 2021-05-26
RU2020110584A3 (enExample) 2021-12-15
KR20200057701A (ko) 2020-05-26

Similar Documents

Publication Publication Date Title
US12297272B2 (en) IgG Fc variants for veterinary use
KR102935714B1 (ko) 수의과 용도를 위한 IgG Fc 변이체
US20240270820A1 (en) Il4/il13 receptor molecule for veterinary use
US20220169740A1 (en) NGF Antagonists for Medical Use
US12428466B2 (en) IL4/IL13 receptor molecule for veterinary use
US20240270819A1 (en) Il4/il13 receptor molecules for veterinary use
CA3121586A1 (en) Erythropoietin analogs for veterinary use
US20110117082A1 (en) Soluble Tumor Necrosis Factor Receptor Mutant
CA3065540A1 (en) Erythropoietin and analogs for veterinary use
KR102959451B1 (ko) 수의과용 igg fc 변이체
RU2814952C2 (ru) ВАРИАНТЫ IgG-FC ДЛЯ ПРИМЕНЕНИЯ В ВЕТЕРИНАРИИ
RU2829812C2 (ru) Антагонисты ngf для медицинского использования
RU2850882C2 (ru) Варианты fc igg для ветеринарного применения

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220831

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241217

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241217

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250414

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250724

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250724

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250808

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250818

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250922

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250922